SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories - Quaterly Results

29 May 2025 Evaluate
The revenue for the March 2025 quarter is pegged at Rs. 20449.40 millions, about 9.45% up against Rs. 18683.30 millions recorded during the year-ago period.Net profit declined -13.71% to Rs. 2258.80 millions from Rs. 2617.70 millions.Operating profit for the quarter ended March 2025 rose to 4083.80 millions as compared to 3924.20 millions of corresponding quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 20449.40 18683.30 9.45 88134.40 79638.50 10.67 88134.40 79638.50 10.67
Other Income 1115.90 837.90 33.18 5070.60 3059.90 65.71 5070.60 3059.90 65.71
PBIDT 4083.80 3924.20 4.07 26632.60 19771.70 34.70 26632.60 19771.70 34.70
Interest 169.10 202.50 -16.49 761.10 800.70 -4.95 761.10 800.70 -4.95
PBDT 3914.70 3596.50 8.85 25871.50 18332.70 41.12 25871.50 18332.70 41.12
Depreciation 916.40 678.00 35.16 2836.10 2391.40 18.60 2836.10 2391.40 18.60
PBT 2998.30 2918.50 2.73 23035.40 15941.30 44.50 23035.40 15941.30 44.50
TAX 739.50 300.80 145.84 2138.20 336.20 535.99 2138.20 336.20 535.99
Deferred Tax 372.00 -133.70 -378.23 -1363.10 -1994.00 -31.64 -1363.10 -1994.00 -31.64
PAT 2258.80 2617.70 -13.71 20897.20 15605.10 33.91 20897.20 15605.10 33.91
Equity 239.10 239.10 0.00 239.10 239.10 0.00 239.10 239.10 0.00
PBIDTM(%) 19.97 21.00 -4.92 30.22 24.83 21.72 30.22 24.83 21.72

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×